

* Physician Name:

Office Contact Person:

Specialty:

Office Phone:

Office Fax:

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462

Danyelza (naxitamab-gqgk)

(800.88.CIGNA) PHYSICIAN INFORMATION PATIENT INFORMATION *Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on * DEA, NPI or TIN: this form are completed.* * Patient Name: * Cigna ID: * Date of Birth: * Patient Street Address:

Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested:] Danyelza	ICD10:			
Dose:Frequency of therapy:Duration of therapy:					
Is this a new start or continuation of therapy? □ new start □ continuation of therapy (if continuation of therapy) Has your patient had a complete or partial response to the medication requested? Yes □ No □ (if complete or partial response) When w as this response noted? Provide date: (if continuation of therapy with a complete or partial response previously noted) Has your patient experienced disease progression after having a complete or partial response? Yes □ No □ Start Date: What is your patient's current w eight?					
Where will this medication be obtained? Prescriber's office stock (billing on a medical claim form) Other (please specify): Home Health / Home Infusion vendor					
Facility and/or doctor dispensing and administering medication: Facility Name: State: Address (City, State and Zip Code):					
Is the patient a candidate for home infusion?YesNoDoes the physician have an in-office infusion site?YesNo					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?					
What is your patient's diagnosis? neuroblastoma other (please specify):					
Clinical Information (if neuroblastoma) Does your patient have high-risk disease? Yes No (if neuroblastoma) Was the neuroblastoma found in the bone or bone marrow? Yes No (if neuroblastoma) Does your patient have relapsed or refractory disease? Yes No (if neuroblastoma) Which of the follow ing best describes how your patient responded to previous treatment (BEFORE starting this drug)? Itumor size changed by less than 25% (either grew or shrank); also know n as "stable disease" Itumor shrank by 26-49% (minor response) Itumor shrank by 50% or more (partial response) Itumor grew by 25% or more Itumor grew by 25% or more					

 Additional pertinent information (including prior therapy, disease stage, performance status, and names/doses/admin schedule of any agents to be used concurrently):

 Attestation: I attest the information provided is true and accurate to the best of my know ledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

 Prescriber Signature:
 Date:

 Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005

v102622

you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.